Compare AbbVie Inc (ABBV) vs American Express Co (AXP) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

American Express (AXP) trades at $340.91, down 0.49% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $4.53 EPS, beating estimates, and maintains robust fundamentals with 15.07% net income margin and 33.97% ROE. Recent news highlights Amex's focus on premium card member experiences and strategic investments in AI for small businesses.

AXP presents a compelling growth story with consistent revenue expansion and strong profitability, though premium valuation metrics (P/E 20.69, P/B 6.72) warrant caution. Analyst consensus leans bullish with a $369.42 price target, representing 8.4% upside potential. Key risks include competitive pressures in payments and sensitivity to economic cycles affecting consumer spending.